Evidence map›Paper›PMID 35072638›Full record

ArticleJMIR public health and surveillance2022

Has Omicron Changed the Evolution of the Pandemic?

Alexander L Lundberg, Ramon Lorenzo-Redondo, Egon A Ozer, Claudia A Hawkins, Judd F Hultquist, Sarah B Welch, P V Vara Prasad, James F Oehmke, Chad J Achenbach, Robert L Murphy and 3 more

Abstract read
In one paragraph

Article in JMIR public health and surveillance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. SARS-CoV-2 genomics and impact on clinical care for COVID-19.The Journal of antimicrobial chemotherapy · 2023
    Article
  13. The Role of Functional Urban Areas in the Spread of COVID-19 Omicron (Northern Spain).Journal of urban health : bulletin of the New York Academy of Medicine · 2023
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Alexander L LundbergBuehler Center for Health Policy and Economics, Robert J. Havey, MD Institute for Global Health, Northwestern University, Chicago, IL, United States.ORCID 0000-0002-9743-8441
Ramon Lorenzo-RedondoDepartment of Medicine, Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.ORCID 0000-0002-5462-9483
Egon A OzerDepartment of Medicine, Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.ORCID 0000-0002-7131-3691
Claudia A HawkinsDepartment of Medicine, Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.ORCID 0000-0001-7228-6317
Judd F HultquistDepartment of Medicine, Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.ORCID 0000-0001-6424-4280
Sarah B WelchBuehler Center for Health Policy and Economics, Robert J. Havey, MD Institute for Global Health, Northwestern University, Chicago, IL, United States.ORCID 0000-0001-5609-3718
P V Vara PrasadSustainable Intensification Innovation Lab, Kansas State University, Manhattan, KS, United States.ORCID 0000-0001-6632-3361
James F OehmkeDepartment of Emergency Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.ORCID 0000-0003-2003-3443
Chad J AchenbachDepartment of Medicine, Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.ORCID 0000-0003-4847-7249
Robert L MurphyDepartment of Medicine, Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.ORCID 0000-0003-3936-2052
Janine I WhiteBuehler Center for Health Policy and Economics, Robert J. Havey, MD Institute for Global Health, Northwestern University, Chicago, IL, United States.ORCID 0000-0002-7204-477X
Robert J HaveyRobert J. Havey, MD Institute for Global Health, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.ORCID 0000-0002-7176-058X
Lori Ann PostBuehler Center for Health Policy and Economics, Robert J. Havey, MD Institute for Global Health, Northwestern University, Chicago, IL, United States.ORCID 0000-0002-6261-3254

Funding

Assessing the Risk of SARS-CoV-2 Remdesivir ResistanceR21AI163912 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HULTQUIST, JUDD F · 2021 to 2022
$440k
NIAID NIH HHS R21 AI163912
6 · The paper itself

Abstract

backgroundVariants of the SARS-CoV-2 virus carry differential risks to public health. The Omicron (B.1.1.529) variant, first identified in Botswana on November 11, 2021, has spread globally faster than any previous variant of concern. Understanding the transmissibility of Omicron is vital in the development of public health policy.

objectiveThe aim of this study is to compare SARS-CoV-2 outbreaks driven by Omicron to those driven by prior variants of concern in terms of both the speed and magnitude of an outbreak.

methodsWe analyzed trends in outbreaks by variant of concern with validated surveillance metrics in several southern African countries. The region offers an ideal setting for a natural experiment given that most outbreaks thus far have been driven primarily by a single variant at a time. With a daily longitudinal data set of new infections, total vaccinations, and cumulative infections in countries in sub-Saharan Africa, we estimated how the emergence of Omicron has altered the trajectory of SARS-CoV-2 outbreaks. We used the Arellano-Bond method to estimate regression coefficients from a dynamic panel model, in which new infections are a function of infections yesterday and last week. We controlled for vaccinations and prior infections in the population. To test whether Omicron has changed the average trajectory of a SARS-CoV-2 outbreak, we included an interaction between an indicator variable for the emergence of Omicron and lagged infections.

resultsThe observed Omicron outbreaks in this study reach the outbreak threshold within 5-10 days after first detection, whereas other variants of concern have taken at least 14 days and up to as many as 35 days. The Omicron outbreaks also reach peak rates of new cases that are roughly 1.5-2 times those of prior variants of concern. Dynamic panel regression estimates confirm Omicron has created a statistically significant shift in viral spread.

conclusionsThe transmissibility of Omicron is markedly higher than prior variants of concern. At the population level, the Omicron outbreaks occurred more quickly and with larger magnitude, despite substantial increases in vaccinations and prior infections, which should have otherwise reduced susceptibility to new infections. Unless public health policies are substantially altered, Omicron outbreaks in other countries are likely to occur with little warning.

Indexed as

COVID-19PandemicsHumansPublic HealthPublic Health SurveillanceSARS-CoV-2BetaCOVID-19DeltaepidemiologyOmicronpandemicpublic healthpublic health surveillanceSARS-CoV-2sub-Saharan Africavariant of concernVOC

Identifiers

PMID35072638
PMCPMC8812144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.